Crossref
Biomarkers and Risk Stratification in the Prognostication of Immune Checkpoint Inhibitors-associated Myocarditis
Diseases & Research · 2026 · 6 (2) · 92-101
DOI: 10.54457/dr.202601004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diseases & Research, 2026. Verfasst von Yin Qian und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Qian, Y., Yuntao, Z., Weiwu, C., Yuehong, K., & Liyuan, Z. (2026). Biomarkers and Risk Stratification in the Prognostication of Immune Checkpoint Inhibitors-associated Myocarditis. Diseases & Research, 6(2), 92-101. https://doi.org/10.54457/dr.202601004
Vancouver
Qian Y, Yuntao Z, Weiwu C, Yuehong K, Liyuan Z. Biomarkers and Risk Stratification in the Prognostication of Immune Checkpoint Inhibitors-associated Myocarditis. Diseases & Research. 2026;6(2):92-101. doi:10.54457/dr.202601004
BibTeX
@article{Qian2026,
author = {Qian, Yin and Yuntao, Zhou and Weiwu, Chen and Yuehong, Kong and Liyuan, Zhang},
title = {Biomarkers and Risk Stratification in the Prognostication of Immune Checkpoint Inhibitors-associated Myocarditis},
journal = {Diseases & Research},
year = {2026},
volume = {6},
number = {2},
pages = {92--101},
doi = {10.54457/dr.202601004}
}
EUVIMED